Relationship of Chronic Hepatitis C Infection to Rates of AIDS-Defining Illnesses in a Canadian Cohort of HIV Seropositive Individuals Receiving Highly Active Antiretroviral Therapy

REFERENCES

• Greub G, Ledergerber B, Battegay M, et al. Clinical pro-gression, survival, and immune recovery during anti-retroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356(9244)1 800–1805.
   Web of Science ®Google Scholar
• De Luca A, Bugarini R, Lepri AC, et al; Italian Cohort Naive Antiretrovirals Study Group. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162(18):2125–2132.
   PubMed Web of Science ®Google Scholar
• Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;33(3):365–372.
   PubMed Web of Science ®Google Scholar
• Fuping G, Wei L, Yang H, Zhifeng Q, Lingyan Z, Yanling L, Taisheng L. Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: multicentric observation cohort. J Acquir Immune Defic Syndr 2010;54(2):137–142.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30\(suppl 1):577–84.
   Google Scholar
• Melvin DC, Lee JK, Belsey E, Arnold J, Murphy RL. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS. 2000; 14(4):463–465.
   PubMed Web of Science ®Google Scholar
• Aceti A, Pasquazzi C, Zechini B, De Bac C; LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002;29(1):41–48.
   PubMed Web of Science ®Google Scholar
• d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, et al; lcorm Foundation Study Group. Risk of developing spe-cific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis. 2009;49(4):612–622.
   PubMed Web of Science ®Google Scholar
• Dorrucci M, Valdarchi C, Suligoi B, et al. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS. 2004;18(17):2313–2318.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis. 2005;41(6):906–911.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002;288(2)199–206.
   Web of Science ®Google Scholar
• Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS. 2002;16(14):1915–1923.
   PubMed Web of Science ®Google Scholar
• Palmer AK, Klein MB, Raboud J, et al, the CANOC Collab-oration. Cohort profile: the Canadian Observational Cohort collaboration [published online ahead of print February 15, 2010]. Int J Epidemiol.
   Google Scholar
• Centres for Disease Control (CDC). 1993 revised classifi-cation system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41(RR-17):1–19.
   Google Scholar
• Herrero-Martinez E, Sabin CA, Evans JG, Griffioen A, Lee CA, Emery VC. The prognostic value of a single hepatitis C virus RNA load measurement taken early after human immunodeficiency virus seroconversion. J Infect Dis. 2002 ;186(4):470–476.
   PubMed Web of Science ®Google Scholar
• Piroth L, Grappin M, Cuzin L, et al. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolu-tion in human immunodeficiency virus-positive patients. J Viral Hepat. 2000;7(4):302–308.
   PubMed Web of Science ®Google Scholar
• Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med. 2004;5(3):174–179.
   PubMed Web of Science ®Google Scholar
• Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18(15):2039–2045.
   PubMed Web of Science ®Google Scholar
• Lincoln D, Petoumenos K, Dore GJ; Australian HIV Obser-vational Database. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003;4(3):241–249.
   PubMedGoogle Scholar
• Rancinan C, Neau D, Saves M, et al; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS. 2002 ;16(10):1357–1362.
   Google Scholar
• Rockstroh JK, Mocroft A, Soriano V, et al; EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiret-roviral therapy. J Infect Dis. 2005;192(6):992–1002.
   PubMed Web of Science ®Google Scholar
• Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS. 2006;20(8)1171–1179.
   Web of Science ®Google Scholar
• Babiker A, Darbyshire J, Pezzotti P, et al; CASCADE Collaboration. Changes over calendar time in the risk of specific first AIDS-defining events following HIV serocon-version, adjusting for competing risks. Int J Epidemiol. 200231(5):951–958.
   Google Scholar
• Gonzalez VD, Landay AL, Sandberg JK. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin ImmunoL 2010;135(1)12–25.
   Web of Science ®Google Scholar
• Szabo G, Dolganiuc A. Hepatitis C and innate immunity: recent advances. Clin Liver Dis. 2008;12(3):675–692, x.
   PubMed Web of Science ®Google Scholar
• Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and N53 proteins. J Leukoc Biol. 2007;82(3):479–487.
   PubMed Web of Science ®Google Scholar
• Perrella A, Sbreglia C, Atripaldi L, et al. Lower CD4+ T-cell number expressing CD7+ characterizes HIV/hepa-titis C virus coinfection compared with HIV and hepatitis C virus monoinfection. J Acquir Immune Defic Syndr. 2006;43(4):504–506.
   PubMed Web of Science ®Google Scholar
• Kovacs A, Karim R, Mack WJ, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis. 2010;201(6):823–834.
   PubMed Web of Science ®Google Scholar
• Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB; Canadian Co-infection Cohort Study Investigators. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after anti-retroviral therapy. AIDS. 2010;24(12)1857–1865.
   Web of Science ®Google Scholar
• Perry W, Hilsabeck RC, Hassanein TI. Cognitive dys-function in chronic hepatitis C: a review. Dig Dis Sci. 2008;53(2):307–321.
   PubMed Web of Science ®Google Scholar
• Butt AA, Evans R, Skanderson M, Shakil AO. Comor-bid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. J Hepatol. 2006;44(5):864–868.
   PubMed Web of Science ®Google Scholar
• Moore DM, Zhang W, Yip B, Genebat M, Lima VD, Montaner JS, Hogg RS. Non-medically supervised treat-ment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11(5):299–307.
   PubMed Web of Science ®Google Scholar
• Small W, Wood E, Betteridge G, Montaner J, Kerr T. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care. 2009;21(6):708–714.
   PubMed Web of Science ®Google Scholar
• D'Amico R, Yang Y, Mildvan D, et al. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconsti-tution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin ImmunoL 2005;25(2)1 06–115.
   Google Scholar
• Ortega KL, Ceballos-Salobrena A, Gaitán-Cepeda LA, Magalhães MG. Oral manifestations after immune reconstitution in HIV patients on HAART. Int J STD AIDS. 200819(5):305–308.
   Google Scholar
• Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis. 2004;4(9):557–565.
   PubMed Web of Science ®Google Scholar
• Franceschi S, Dal Maso L, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008;99(5):800–804.
   PubMed Web of Science ®Google Scholar
• Goossens VJ, Schreij G, van der Geest S, et al. A delay in CD4 cell response after initiation of highly active anti-retroviral therapy is associated with the presence of anti-cytomegalovirus but not with anti-herpes simplex virus antibodies. AIDS. 2002;16(12):1682–1684.
   PubMed Web of Science ®Google Scholar
• Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual trans-mission. Nat Med. 1996;2(8):918–924.
   PubMed Web of Science ®Google Scholar
• Nerurkar LS, Biggar RJ, Goedert JJ, et al. Antiviral antibod-ies in the sera of homosexual men: correlation with their lifestyle and drug usage. J Med Virol. 1987;21(2):123–135.
   PubMed Web of Science ®Google Scholar
• Russell DB, Tabrizi SN, Russell JM, Garland SM. Serop-revalence of herpes simplex virus types 1 and 2 in HIV-infected and uninfected homosexual men in a primary care setting. J Clin Virol. 2001;22(3):305–313.
   PubMed Web of Science ®Google Scholar
• Lang DJ, Kovacs AA, Zaia JA, et al; Transfusion Safety Study Group. Seroepidemiologic studies of cytomega-lovirus and Epstein-Barr virus infections in relation to human immunodeficiency virus type 1 infection in selected recipient populations. J Acquir Immune Defic Syndr. 1989;2 (6):540–549.
   PubMed Web of Science ®Google Scholar
• British Columbia Centre for Excellence in HIV/AIDS. Thera-peutic Guidelines for Opportunistic Infections. http://www.cfenet.ubc.ca/sites/default/files/uploads/docs/Opportu-nistic_Infection_Therapeutic_Guidelines.pdf. 2007.
   Google Scholar
• Boulos D, Yan P, Schanzer D, Remis RS, Archibald CP. Estimates of HIV prevalence and incidence in Canada, 2005. Can Commun Dis Rep. 2006;32(15)165–174.
   Google Scholar